Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and S-1 Induction in LA-HNSCC
NCT03267121Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2017
- Primary completion
- Sep 2020
- Countries
- 1
- Sponsor
- Shanghai Ninth People's Hospital
- Modality
- Small Molecules
- Drugs
- Rivoceranib
- Conditions
- head and neck squamous cell carcinoma (HNSCC)
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Objective Response Rate at 9 weeks. Started Oct 2017; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Study Group
Apatinib + Tegafur gimeracil oteracil induction chemotherapy
03
Who it enrols
Patients with histologically confirmed locally advanced SCCHN who are surgically unresectable or refuse surgery, with ECOG 0-1 and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Secondary
Number of Participants With at Least One Grade 3-4 Toxicity
Progression Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT03267121.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267121.